The Rise of South Korea in ADC: Mapping Innovation, Platforms & Manufacturing Leaders (2026)
Mapping the Next Global Hub for Antibody-Drug Conjugate Innovation & Manufacturing
The global race for antibody-drug conjugates (ADCs) is accelerating at an unprecedented pace. As oncology pipelines become increasingly complex and targeted therapies move toward precision medicine, ADCs have emerged as one of the most promising and commercially viable modalities in biopharmaceutical development.
However, while innovation continues to surge, one critical bottleneck remains: manufacturing capability and scalability.
In this evolving landscape, South Korea is rapidly positioning itself as a global powerhouse for ADC development and manufacturing. With a unique combination of world-scale CDMO infrastructure, cutting-edge linker and payload technologies, and a growing pool of clinical-stage innovators, Korea is one of the few ecosystems in Asia capable of supporting the entire ADC value chain — from discovery to commercial production.
This report provides a curated overview of the Top 30 ADC companies in Korea, spanning:
- Global CDMOs scaling next-generation biologics manufacturing
- Clinical-stage biotech innovators advancing ADC pipelines
- Platform technology companies enabling differentiation in linker, payload, and conjugation
More importantly, this landscape highlights a critical shift:
Korea is no longer just a manufacturing base — it is becoming a strategic partner for global ADC development.
For biopharma companies seeking reliable manufacturing partners, for technology providers enabling ADC innovation, and for investors tracking the next wave of oncology breakthroughs, understanding Korea’s ADC ecosystem is no longer optional — it is essential.
As the industry moves toward more complex, high-potency biologics, and as demand for integrated ADC capabilities continues to grow, Korea stands at the center of this transformation.
Korea ADC Landscape Report 2026
A Strategic Overview of Antibody-Drug Conjugate (ADC) Players in South Korea South Korea is rapidly emerging as a global hub for ADC innovation and manufacturing. This report provides a curated overview of the top 30 ADC companies across CDMOs, biotech innovators, and platform technology providers.
Join leading ADC experts at Biologics Manufacturing Korea 2026. Connect with CDMOs, biotech innovators, and technology providers shaping the future of ADC manufacturing in Asia
#ADCBio2026 brings East Asia’s top experts together to advance ADC innovation and collaboration across biopharma, CMOs/CROs, regulators, and academia.
📍 Songdo Convensia, Incheon, South Korea 📆 17 - 18 September 2026
Share With Your Network
